KEY POINTS
  • Bristol-Myers Squibb CEO Giovanni Caforio tells CNBC's Jim Cramer that the $74 billion bid for Celgene is a strategic move.
  • "It creates the number one company in oncology, number one cardiovascular franchise, very strong presence in autoimmune diseases," he says in an interview on "Mad Money."
  • Cramer explains why investors ditching retail stocks might be playing into a number of those company's hands.

Bristol-Myers Squibb CEO Giovanni Caforio defended his company's $74 billion bid for cancer drug maker Celgene in an interview with CNBC's Jim Cramer on Wednesday.

The move is facing opposition from the Wellington Management, Bristol-Myers' largest stakeholder, and Starboard Value hedge funds. The acquisition, which will be voted on by shareholders next week, would add a large load of debt to the company's balance sheet.